More than $1 billion! Lilly is licensed exclusively by Xinda BioPD-1 Mono-Anti-China.

On August 18th Thyme Bio and Eli Lilly and Company announced that they would expand their strategic partnership on the immuno-oncology drug anti-PD-1 monoclonal antibody Dabershu (Xindili monoanti).
the agreement, Lilly will receive exclusive licenses from Xindi lisan resistance outside China, and Thyda Bio will receive a cumulative total of more than $1 billion.
Dcidelli Monoanti is an innovative biopharmaceutical jointly developed by Thysinda Biopharmaceuticals and Lilly Pharmaceuticals in China, and the first result of the cooperation between the two companies.
the drug was approved in China at the end of 2018 for the treatment of relapsed/resuscidable classic Hodgkin's lymphoma and was selected in the 2019 edition of the China Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of lymphoma.
, Xindili monoanti is the only PD-1 inhibitor that enters China's national health insurance list.
In addition, two new adaptive applications for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC) and the joint treatment of first-line squamous NSCLC patients by Xindili monoantigen and Gissitalbin have also been accepted by the State Drug Administration (NMPA).
has a long history of collaboration between Xinda Bio and Lilly.
in this expanded strategic partnership, Thyme Bio will grant lilies exclusive licenses outside China, and Lilly will work to bring Xindley monoantitons to North America, Europe and beyond.
under the terms of the contract agreement, Xinta Bio will receive a cumulative total of more than $1 billion, including a down payment of $200 million and a development and sales milestone payment of up to $825 million.
addition, Xinha Bio will receive a double-digit percentage of net sales.
both parties will reserve the right to develop products in the Syndilly monoanti-anti-joint and other partners' products in their respective pipelines.
Currently, Cinda Bio has more than 20 clinical studies (more than 10 of which are registered clinical trials) under way to assess the effectiveness and safety of Syndicate monoanti on a variety of tumors, including the study of Syndicate Monoantigen Lilly Libita (injected with Python di sodium) and platinum first-line treatment of non-squamous non-small cell lung cancer.
Xinda Bio is also conducting clinical research on Xindili monoantigen injections around the world.
August 8, 2020, the two sides announced the results of the ORIENT-11 study in oral presentation at the 21st World Lung Cancer Congress (IASLC WCLC) Online Theme Forum.
ORIENT-11 is a randomized, double-blind, phase 3 controlled clinical study compared to the first-line treatment of non-squamous non-small cell lung cancer without EGFR-sensitive mutations or APK gene rearracing.
Based on an in-period analysis conducted by the Independent Data Monitoring Board (IDMC), The in-period analysis of DDLI monoantigen-force bitay and platinum-type contrast placebo-combined libita and platinum significantly extended progression-free lifetime (PFS) to meet preset efficiency standards.
China's State Drug Administration (NMPA) has officially accepted the listing application for non-scaly NSCLC first-line treatment on April 23, 2020.
and Lilly look forward to submitting applications for the allergy and other allergies in the U.S. and other countries in the future.
same time, NMPA officially accepted applications for new adaptations to the first-line treatment of squamous non-small cell lung cancer in August 2020 for Thessili monoantigen (injection with gisithambin) and platinum chemotherapy.
: Xinda Bio and Lilly Pharmaceuticals announce the expansion of global strategic cooperation on dabershu® (Syndicate monoantigen injections). Retrieved Aug 18, 2020, from the public press release of Xinda Bio.